Open AccessA Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial)
Author(s) -
Hiroomi Okuyama,
Masafumi Ikeda,
Takuji Okusaka,
Masayuki Furukawa,
Shinichi Ohkawa,
Ayumu Hosokawa,
Yasushi Kojima,
Hiroki Hara,
Gou Murohisa,
Kazuhiko Shioji,
Akinori Asagi,
Nobumasa Mizuno,
Masaru Kojima,
T. Yamanaka,
Junji Furuse
Publication year - 2020
Publication title -
neuroendocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.493
H-Index - 101
eISSN - 1423-0194
pISSN - 0028-3835
DOI - 10.1159/000505550
Subject(s) - everolimus , medicine , gastroenterology , chemotherapy , clinical endpoint , neuroendocrine tumors , progression free survival , refractory (planetary science) , clinical trial , physics , astrobiology
Platinum-containing regimens are widely used as first-line chemotherapy for unresectable pancreatic neuroendocrine carcinoma (NEC), but second-line chemotherapies have yet to be established.